Incyte is gunning for a first-in-class nod for PD-1 inhibitor Zynyz in anal cancer again after being turned away by the FDA in 2021. The addition of Zynyz to chemotherapy significantly reduced the ...
Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. Yet company CEO Hervé Hoppenot views the antibody molecule not necessarily as a major revenue driver but as an aide to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results